Chordate enrolls first patients in a randomized, placebo-controlled, double-blind, multicenter study to evaluate the efficacy of intranasal kinetic oscillation stimulation in the treatment of chronic non-allergic rhinitis

Data Anticipated Q4 2019
Kista, Sweden, May 08, 2018 - Chordate Medical Holding AB's (publ) ("Chordate"), a specialty medtech company that focuses on developing and commercializing neuromodulating treatment systems for treating non-allergic rhinitis and migraine, today announced that the first patients were enrolled in Chordate's clinical study of its Kinetic Oscillation Stimulation System S101 (KOS-treatment), an investigative product, in patients with diagnosed chronic non-allergic rhinitis.

"To now get started with the first patients at the University Hospitals in Helsinki and Kuopio, Finland, is very important in our long-term securing of scientific evidence. We know from previous studies, and our own and others' clinical experiences in practice, that we make significant difference for this very large patient group. We are now building further on this with the aim to produce a clear scientific basis for our continued business journey", says Anders Weilandt, CEO of Chordate.

The randomized, placebo-controlled, double-blind, multicenter study is being conducted at fourteen ENT university clinics in Finland, UK, The Netherlands, Italy and the Czech Republic. Coordinating investigator is Professor Claire Hopkins at Guys Hospital, London and study advisor is Professor Mats Holmström at the Karolinska Institute, Stockholm. The study intends to enroll up to 300 subjects and is designed to evaluate the efficacy and safety of the KOS-treatment. The primary endpoint is to detect weekly median change in a set of evaluation criteria from baseline, with a series of two consecutive treatments, until the third month follow-up visit. The total follow-up period of each patient is twelve months. Patients in the KOS arm will receive active treatment from the S101, while patients receiving placebo treatment will be given a validated sham treatment from the same equipment.

For more information, please contact:
Anders Weilandt, CEO
anders.weilandt@chordate.com 
Phone: +46 (0) 733 87 42 77

Information:
This information is information that Chordate Medical Holding AB (publ) is required to disclose under the EU Market Abuse Regulation. The information was provided, through the contact person above for publication on May 08, 2018 at. 14:45 CET.

TO THE EDITORS
About Chordate
Chordate Medical Holding AB (publ) is a medical technology company that during ten years has developed, patented and CE-marked a new treatment method for chronic nasal congestion through nerve stimulation. The company sells its product system including treatments through its own sales organization as well as distributors to clinics and hospitals, which in their turn treat patients. Read more at www.chordate.com.  Mangold Fondkommission AB, tel. +46 8 5030 1550, is the company's mentor and liquidity guarantee at NGM Nordic MTF.

2018-08-14
Regulatorisk

Kista, 14 augusti 2018. Severn Healthcare Technologies Ltd. ("Severn") och Chordate Medical Holding AB (publ) har genom Dotterbolaget Chordate Medical AB ("Chordate") träffat ett exklusivt distributionsavtal för försäljning av Chordates produkter i Storbritannien och Irland. Severn är ett av Storbritanniens mest snabbväxande medicintekniska distributörsbolag med tydligt fokus på Öron-Näsa-Halsmarknaden ("ÖNH").

2018-08-14
Regulatory

Kista, August 14, 2018. Severn Healthcare Technologies Ltd. ("Severn") and Chordate Medical Holding AB (publ) have signed an exclusive distribution agreement for Chordate's products in UK and Ireland through the subsidiary Chordate Medical AB ("Chordate"). Severn is one of UK's fastest-growing medical technology distributors, with focus on the Ear-Nose-Throat ("ENT") Market.

2018-07-12
Regulatorisk

Chordate Medical Holding AB (publ) genomförde tidigare i år en företrädesemission samt en riktad kvittningsemission där aktieägare och investerare kunde teckna units. Emissionerna registrerades hos Bolagsverket i juli. Varje unit består av en nyemitterad aktie och en teckningsoption. Totalt emitterades 11 520 845 units i emissionerna (tidigare kommunicerades 9 853 918 units), och därmed finns lika många teckningsoptioner.

2018-06-07
Regulatorisk

Chordate Medical Holding AB (publ) har i maj/juni 2018 genomfört en företrädesemission vilket tillför bolaget ca 19 MSEK före emissionskostnader och kvittningar.

2018-05-30
Regulatorisk
Med anledning av Chordate Medical Holding ABs (publ) ("Chordate") avtal om att bilda ett joint venture med Nanos Medical (Shanghai) Limited ("Nanos Medical") avseende främst den kinesiska marknaden utvecklar Chordates VD Anders Weilandt avtalets innebörd och potential i följande videointervju.
2018-05-28
Regulatorisk

Chordate Medical Holding AB (publ) ("Chordate") har tecknat avtal om att bilda ett joint venture med Nanos Medical (Shanghai) Limited ("Nanos Medical"), avseende främst Kina. Med anledning av att detta avtal som Chordate anser vara strategiskt viktigt och som rimligen väsentligt kommer påverka verksamheten positivt över tid, förlängs den nu pågående teckningsperioden fram till 1 juni 2018.

2018-05-25
Regulatorisk

Sammanfattning av kvartalet januari-mars 2018

  • Nettoomsättningen uppgick till 194 369 SEK (272 585)
  • Kassaflöde från den löpande verksamheten var -3 880 599 SEK (-8 442 419)
  • Resultat efter finansiella poster var SEK -6 855 583 (-4 409 503)
  • Resultat efter skatt var SEK -6 855 583 (-4 409 503)
  • Resultat per aktie var SEK -1,89 (-1,66)
2018-05-24
Regulatorisk

Chordate Medical Holding AB (publ) ("Chordate") har genom sitt dotterbolag Chordate Medical AB tecknat avtal om samägande av ett nyregistrerat Shanghai-baserade bolag i joint venture med Nanos Medical (Shanghai) Limited ("Nanos Medical"), avseende främst den kinesiska marknaden. Nanos Medical investerar MUSD 1,5 ca 67 procent av det samägda bolaget medan Chordate för sin andel om 33 procent tillför en sina åtta kinesiska patent. Bedömningen är att försäljning på den kinesiska marknaden kan påbörjas inom 3 år.

2018-05-24
Regulatory

Chordate Medical Holding AB (publ) ("Chordate") has, through its subsidiary Chordate Medical AB, signed an agreement of co-ownership of a newly registered Shanghai-based company in a Joint venture with Nanos Medical (Shanghai) Limited (' Nanos Medical '), primarily concerning the Chinese market. Nanos Medical invests MUSD 1.5 for about 67 percent ownership of the joint venture, while Chordate for its share of 33 percent adds their eight Chinese patents. The parties assess that sales can commence within 3 years in the Chinese market.

2018-05-22
Regulatorisk

Chordate Medical Holding AB (Publ) meddelar att man kommer att delta på G&W Småbolagsfrukost på IVA konferenscenter, Grev Turegatan 16 i Stockholm den 24 maj, kl. 09.00 och presenterar senaste utvecklingen och framtid i bolaget.

2018-05-22
Regulatorisk

Chordate Medical Holding AB (Publ) meddelar att man kommer att delta på G&W Småbolagsfrukost på IVA konferenscenter, Grev Turegatan 16 i Stockholm den 24 maj, kl. 12.00 och presenterar senaste utvecklingen och framtid i bolaget.

<<
1
...
3
4
5
6
...
9
>>

Prenumerera

Pressmeddelanden och rapporter via E-post.

Investor relations